Hsp10, Hsp70, and Hsp90 immunohistochemical levels change in ulcerative colitis after therapy

G. Tomasello, C. Sciumè, F. Rappa, V. Rodolico, M. Zerilli, A. Martorana, G. Cicero, R. de Luca, P. Damiani, F. M. Accardo, M. Romeo, F. Farina, G. Bonaventura, G. Modica, G. Zummo, E. Conway de Macario, A. J L Macario, F. Cappello

Research output: Contribution to journalArticlepeer-review


Ulcerative colitis (UC) is a form of inflammatory bowel disease (IBD) characterized by damage of large bowel mucosa and frequent extra-intestinal autoimmune comorbidities. The role played in IBD pathogenesis by molecular chaperones known to interact with components of the immune system involved in inflammation is unclear. We previously demonstrated that mucosal Hsp60 decreases in UC patients treated with conventional therapies (mesalazine, probiotics), suggesting that this chaperonin could be a reliable biomarker useful for monitoring response to treatment, and that it might play a role in pathogenesis. In the present work we investigated three other heat shock protein/molecular chaperones: Hsp10, Hsp70, and Hsp90. We found that the levels of these proteins are increased in UC patients at the time of diagnosis and decrease after therapy, supporting the notion that these proteins deserve attention in the study of the mechanisms that promote the development and maintenance of IBD, and as biomarkers of this disease (e.g., to monitor response to treatment at the histological level).

Original languageEnglish
Pages (from-to)210-214
Number of pages5
JournalEuropean journal of histochemistry : EJH
Issue number4
Publication statusPublished - 2011


  • Comorbidity
  • Heat shock proteins
  • Hsp
  • Inflammation
  • Molecular chaperones
  • Ulcerative colitis

ASJC Scopus subject areas

  • Cell Biology
  • Histology
  • Biophysics


Dive into the research topics of 'Hsp10, Hsp70, and Hsp90 immunohistochemical levels change in ulcerative colitis after therapy'. Together they form a unique fingerprint.

Cite this